Press release
FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now Accessible in Southern Florida
West Palm Beach, FL - May 5, 2025 - Brain Power Clinics, a Florida-based healthcare provider specializing in cognitive conditions, announces the availability of TB006 for compassionate use in the treatment of Alzheimer's disease. The new drug, currently in clinical trials, has shown promising early results in addressing memory loss and other symptoms associated with dementia.Promising New Treatment for Alzheimer's Disease
TB006, now available through Brain Power Clinics in Southern Florida, is designed to reduce inflammation in the brain by targeting galectin3, a protein linked to Alzheimer's pathology. This mechanism may help dissolve the amyloid plaques and tau tangles that contribute to cognitive decline.
According to Dr. Arbella Sarkis, the chief investigator in the ongoing clinical trial, more than 400 patients have received TB006 with no reported side effects. "Approximately 70-80% of participants have experienced improvement in cognitive functions," Dr. Sarkis stated.
Expert and Community Endorsements
Dr. Josh Helman, a Harvard-trained physician, has presented findings related to TB006 at A4M, a conference focused on anti-aging medical advancements. His presentation received strong interest due to the drug's potential in helping individuals with early-stage dementia and memory impairment. Dr. Helman is the Chief Medical Officer of Brain Power Clinics. He has been treating patients with TB006 over the past year, and has seen excellent results in his patients.
Philanthropic support has also grown. Robert Buechner, Chairman of The BeEx Foundation and a long-time advocate for Alzheimer's research, has backed the initiative. "For the first time in decades, we are seeing encouraging results that deserve wider attention," Buechner said.
Access Remains Limited but Growing
Despite the positive data, TB006 is still in a controlled trial phase, limiting the number of healthcare providers who can offer it. Brain Power Clinics is currently one of the few centers in the U.S. administering the treatment.
Preliminary results shared by the drug's manufacturer show that patients receiving TB006 demonstrated improved cognitive performance and reduced brain inflammation after three months of use compared to a placebo group. However, broader trials are needed to validate long-term outcomes.
Patients and families dealing with memory challenges or early signs of Alzheimer's are encouraged to learn more about eligibility and access.
Text "Memory" to 728-203-3131 or visit www.BrainPowerClinics.com [http://www.brainpowerclinics.com/] for more information.
About Brain Power Clinics
Brain Power Clinics, based in Palm Beach County, Florida, focuses on diagnosing and supporting individuals with dementia, cognitive decline, and memory-related issues. The clinic is dedicated to providing access to cutting-edge treatments under FDA oversight and compassionate use protocols.
Media Contact
Company Name: Brain Power Clinics
Contact Person: Dr. Robert Love
Email: Send Email [http://www.universalpressrelease.com/?pr=fda-grants-compassionate-use-of-alzheimers-drug-tb006-now-accessible-in-southern-florida]
Phone: 728-203-3131
Country: United States
Website: http://www.brainpowerclinics.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now Accessible in Southern Florida here
News-ID: 4000167 • Views: …
More Releases from Getnews
Extended Family Home Care Announces Strengthened Commitment to Quality Senior Su …
Image: https://www.globalnewslines.com/uploads/2026/01/1767982014.jpg
Extended Family Home Care has announced an enhanced focus on compassionate, dependable in-home support designed to elevate daily living for seniors across the Denver community. Known for exceptional service standards and personalized care planning, the organization continues to expand resources to better serve aging adults and their families.
As part of this initiative, the company has highlighted essential service information through key offerings, including Extended Family Home Care Denver [https://www.google.com/maps?cid=18414623585048068962],…
Landit.ai Welcomes Briana Atkins to Marketing Team
Image: https://www.globalnewslines.com/uploads/2026/01/1767973611.jpg
New hire brings editorial and media production experience to support brand and content strategy
New York, NY - Landit.ai, an AI-powered interview coaching platform, announced today that Briana Atkins has joined the company, contributing to marketing strategy, social media, and content development as the company continues to scale its user-facing communications.
Briana brings a background in writing, media production, and editorial work, supporting Landit.ai's marketing initiatives and brand storytelling efforts. In…
Smyrna Homeowners Trust First State Roofing & Exteriors Co. for Fast, Affordable …
Image: https://www.globalnewslines.com/uploads/2026/01/1767995738.jpg
Smyrna, DE - January 9, 2026 - First State Roofing & Exteriors Co. in Smyrna [https://firststateroofingexteriors.com/] is quickly becoming the go-to provider for homeowners searching for "gutter repair near me" in the Smyrna area. With a reputation built on reliability, exceptional craftsmanship, and unmatched customer service, the company is leading the charge in keeping Georgia homes safe from water damage through expert gutter repair and maintenance.
Addressing a Critical Need…
Hydronos Corporation Redefining Modern Leak Detection and Setting a New Industry …
Few companies enter an industry and make themselves impossible to ignore. Hydronos Corporation did it in under four months. As 2025 comes to an end, The Leak Authority stands out as one of the fastest-growing, most in-demand leak-diagnostic teams in Northern California
Image: https://www.globalnewslines.com/uploads/2026/01/40cb6c0d9acc864ee6c8604f554befe6.jpg
As 2025 comes to a close, Hydronos Corporation stands as one of the most ambitious, resilient, and forward-thinking companies in the leak-detection world. What began as a bold…
More Releases for TB006
Alzheimer's Disease Competitive Landscape 2025: Clinical Trial Analysis, Therapi …
(Albany, USA) DelveInsight's latest report, "Alzheimer's Disease Pipeline Insight 2025", provides an in-depth and data-driven analysis of the global Alzheimer's disease (AD) clinical trial landscape, highlighting key EMA, FDA, and PDMA regulatory updates, emerging therapies, and market trends shaping the future of Alzheimer's treatment.
With 110+ active players and over 120 pipeline drugs under development, the Alzheimer's therapeutic domain continues to evolve with rapid advancements in disease-modifying treatments, biomarkers, and neuroprotective…
Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA Approvals, Treatment Ma …
(Albany, USA) DelveInsight's 'Alzheimer's disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Alzheimer's disease therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Alzheimer's disease pipeline domain.
For Alzheimer's disease emerging drugs, the Alzheimer's disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration,…
New Investigational Drug TB006 FDA - Approved For Compassionate Use
Naples, FL - April 21, 2025 - TB006, a new investigational drug, has been approved by the US Food and Drug Administration (FDA) for compassionate use and is currently being evaluated in a clinical trial for Alzheimer's disease. The FDA's compassionate use designation allows patients with serious or life-threatening conditions to access investigational treatments when no satisfactory alternatives are available.
TB006 is currently undergoing clinical trials to assess its safety and…
Alzheimer's Disease Drug Development Pipeline: 2025-A Surge in Innovation as 110 …
DelveInsight unveils its latest report, highlighting the evolving landscape of the Alzheimer's disease pipeline, with over 110 pharma and biotech companies like BioVie, Novo Nordisk, Alector, Longeveron, Cognition Therapeutics, TrueBinding, VT BIO, Luye Pharma Group, Lexeo Therapeutics, Merck Sharp & Dohme LLC, and Regeneration Biomedical, advancing novel Alzheimer's disease drugs set to reshape the Alzheimer's disease market.
The fight against Alzheimer's disease is gaining momentum. In its newly released "Alzheimer's disease…
Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Land …
The Dementia Market size was valued approximately USD 21 million in 2021 and the report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the 7MM.
DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy,…
Ischemic Stroke Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Ischemic Stroke Pipeline Report
• Over 50+ Ischemic Stroke…
